Therapeutic Drugs Business Unit

Pharmaceutical Business
Otsuka People Creating New Products for Better Health Worldwide

Providing breakthrough treatments for patients around the world

Otsuka Pharmaceutical is dedicated to the research & development of highly-innovative drugs and diagnostics. Leveraging our research culture of curiosity, determination and unconventional thinking, we strive for solutions that only Otsuka can deliver, to improve the health of people across the world.
Our R&D philosophy places emphasis on encouraging individual researchers to take the untraveled path, pursuing fresh ideas within a collaborative, accommodating environment. Supported by the global integration of our research and development institutes in Asia, the U.S. and Europe, the result has been epoch-making drugs

Pletaal, discovered by Otsuka, inhibits platelet aggregation and has peripheral vasodilator effects. In Japan it was launched in 1988 for the treatment of symptoms associated with chronic arterial obs...

Anti-gastritis and anti-gastric ulcer agent Otsuka-discovered Mucosta has an action that protects the gastric mucosa in addition to suppressing free radicals and inflammation in the stomach. It was l...

ABILIFY is an antipsychotic with the world's first dopamine D2 receptor partial agonist action, which was discovered by Otsuka. Launched in the U.S. in 2002, ABILIFY is FDA approved in schizophrenia, ...

CopyRight @ OTSUKA 2020
Powered By : Idea World Web